NCT03616795View on ClinicalTrials.gov

Study of LY3154207 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

November 5, 2018

Study Completion Date

November 5, 2018

Conditions
Healthy
Interventions
DRUG

LY3154207

Administered orally

DRUG

[14C]-LY3154207

Administered orally

Trial Locations (1)

53704

Covance Clinical Research Inc, Madison

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03616795 - Study of LY3154207 in Healthy Participants | Biotech Hunter | Biotech Hunter